French startup Klineo raises ¬2 million to revolutionize access to clinical trials for cancer patients
Its AI-powered platform connects doctors and patients directly to relevant trials in less than a minute.
French healthtech Klineo announced on Monday the raising of €2 million with the aim of improving equity in access to clinical trials for cancer patients.
Its AI-powered platform connects doctors and patients directly to relevant trials in less than a minute. Fast and intuitive, this solution democratizes access to new treatments for patients.
This funding will allow Klineo to expand its solution to all types of cancer, in a context in which the number of patients and clinical trials is experiencing significant growth, both in France and in other countries around the world.
Follow us on: 
Why be part of clinical trials?
Clinical trials offer the opportunity to benefit from the latest therapeutic innovations. But today, only a minority of cancer patients (<5%) participan en ensayos clínicos, mientras que la mayoría de los pacientes (>70%) would be willing to participate if they knew about them. However, up to 20% of trials fail, due to lack of participants.
This is precisely the problem that Klineo aims to address with a solution that simplifies the previously complex and time-consuming trial search process for both patients and clinicians.
According to Dr. Arnaud Bayle, co-founder of Klineo and oncologist, “Today, very few patients benefit from a clinical trial because finding one is such a complex process. At Klineo, we offer a reliable, intuitive and fast solution that ultimately gives doctors and patients, wherever they are treated, the ability to easily find new therapeutic options tailored to each situation, and ultimately allows medical research to move forward.”
A fast, intuitive and free solution
The platform consists of two separate interfaces, one for healthcare professionals and one for patients. Klineo allows you to search for trials and establish direct contact with the centers where clinical trials are open.
Klineo’s platform maintains a list of all open clinical trials in France, with real-time updates and notifications for users in case of a new clinical trial that matches the patient’s criteria.
Its intuitive interface and proprietary matching algorithms ensure a fast and efficient search, ensuring a match between the patient’s profile and the selected clinical trials.
“The trust and support of our investors reflects the importance of our mission: to ensure fair access to clinical trials. This round of funding will allow us to expand our platform to all types of cancer, thus accelerating the inclusion of patients in clinical trials,” says Thomas Peyresblanques, CEO of Klineo.
An Investment to Extend Its Reach to All Types of Cancer
The €2 million raised from BPI and angel investors will enable Klineo to cover all types of cancers in France by the end of 2024, with a future extension close to lung cancer.
The company is then expected to expand to other countries (Europe, USA, etc.) and other pathologies (rare and neurological diseases, etc.). In addition, the funds will allow Klineo to expand its team and continue to improve the platform both medically and technologically.